Publications by authors named "Patrick Larson"

Claim this Profile
S
Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.
Johannes F Scheid, Kiki Cunningham-Bussel, Nancy Kim, Shiuli Agarwal, Garrett Nieddu, Patrick Larson

Immunohorizons· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Placebo-Controlled, Short-Term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naïve HIV-Infected Participants.
Dirk Schürmann, Andreas Hüser, Frieder Pfäfflin, Caroline Cilissen, Inge De Lepeleire, Patrick J Larson

AIDS Res Hum Retroviruses· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Trial to Evaluate the Relationship Between Fluoride Intake and Urinary Fluoride Excretion in Healthy Participants.
Gillian Gillespie, Deanne Jackson Rudd, Saijuan Zhang, Andrea Schaeffer, Charles Tomek, Patrick Larson

J Clin Pharmacol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK-8507, an Investigational, Oral, Once-Weekly Nonnucleoside Reverse Transcriptase Inhibitor.
Gillian Gillespie, Deanne Jackson Rudd, Saijuan Zhang, Andrea Schaeffer, Charles Tomek, Patrick Larson

J Clin Pharmacol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment.
Daniel A Tatosian, Ka Lai Yee, Zufei Zhang, Kate Mostoller, Erina Paul, Patrick Larson

Clin Pharmacol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anchored Aluminum Catalyzed Meerwein-Ponndorf-Verley Reduction at the Metal Nodes of Robust MOFs.
Patrick J Larson, Joseph L Cheney, Amanda D French, David M Klein, Benjamin J Wylie

Inorg Chem· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir.
Rajesh Krishna, Matthew L Rizk, Patrick Larson, Valerie Schulz, Filippos Kesisoglou

Clin Pharmacol Drug Dev· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the Use of Group Sequential Study Designs for the Test of Bioequivalence for Complicated Products.
Rajesh Krishna, Wen-Lin Luo, Patrick J Larson, Paul H Fackler

J Pharm Sci· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical safety and vasoconstrictive assay-based bioequivalence of a new reformulated mometasone cream.
Rajesh Krishna, Ann Horowitz, Patrick Larson, James Bolognese, Eugene E Marcantonio

Drug Dev Ind Pharm· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir.
Rajesh Krishna, Lilly East, Patrick Larson, Tara Siringhaus, Lisa Herpok

Biopharm Drug Dispos· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.
Rajesh Krishna, Lilly East, Patrick Larson, Chandni Valiathan, Kathleen Deschamps

Biopharm Drug Dispos· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
Rajesh Krishna, Lilly East, Patrick Larson, Chandni Valiathan, Kristin Butterfield

J Pharm Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir.
Rajesh Krishna, Matthew L Rizk, Patrick J Larson, Valerie Schulz, Evan Friedman

Ther Innov Regul Sci· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.
Brett Lauring, Xiujiang Susie Li, Yang Liu, Christy Corr, Nicole Lazarus, Patrick Larson

J Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
Brett Lauring, Yang Liu, Xiujiang Susie Li, Patrick Larson, Allison Moreau

J Clin Pharmacol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A microwave powered injectable neural stimulator.
Bruce C Towe, Patrick J Larson, Daniel W Gulick

Annu Int Conf IEEE Eng Med Biol Soc· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?
Evan J Friedman, Iain P Fraser, Ying-Hong Wang, Arthur J Bergman, Chi-Chung Li, Patrick J Larson

J Clin Pharmacol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability of alendronate and vitamin D(3) in an alendronate/vitamin D(3) combination tablet.
Andrew E Denker, Nicole Lazarus, Arturo Porras, Rohini Ramakrishnan, Marvin Constanzer, Patrick Larson

J Clin Pharmacol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children.
Meranda Nakhla, Andrew E Denker, James D Connor, Thomas O Carpenter, Philip D Walson, Patrick Larson

Clin Ther· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.
Elizabeth Migoya, Patrick Larson, Arthur Bergman, Jutta Miller, Amy O Johnson-Levonas

J Clin Pharmacol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Gary A Herman, Goutam C Mistry, Bingming Yi, Arthur J Bergman, Amy Q Wang, Patrick J Larson

Br J Clin Pharmacol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wireless ultrasound-powered biotelemetry for implants.
Bruce C Towe, Patrick J Larson, Daniel W Gulick

Annu Int Conf IEEE Eng Med Biol Soc· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Brett Lauring, Victor Dishy, Wen-Lin Luo, Omar Laterza, Jaclyn Patterson, Patrick Larson

J Clin Pharmacol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants.
Jules Schwartz, Thomas Hunt, William B Smith, Peggy Wong, Patrick Larson

J Clin Pharmacol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.
Jules I Schwartz, Aimee L Dallob, Patrick J Larson, Omar F Laterza, Jutta Miller

J Clin Pharmacol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis